Zacks Small Cap Comments on CEL-SCI Co.’s FY2024 Earnings (NYSE:CVM)

CEL-SCI Co. (NYSE:CVM) – Stock analysts at Zacks Small Cap dropped their FY2024 earnings per share (EPS) estimates for shares of CEL-SCI in a research report issued to clients and investors on Monday, April 15th. Zacks Small Cap analyst J. Vandermosten now expects that the company will post earnings of ($0.51) per share for the year, down from their previous forecast of ($0.48). The consensus estimate for CEL-SCI’s current full-year earnings is ($0.48) per share.

Separately, StockNews.com lowered CEL-SCI from a “hold” rating to a “sell” rating in a research note on Friday, March 15th.

CEL-SCI Stock Down 1.3 %

CVM opened at $1.50 on Wednesday. The company has a debt-to-equity ratio of 0.75, a current ratio of 1.26 and a quick ratio of 0.78. The stock has a market capitalization of $80.97 million, a price-to-earnings ratio of -2.21 and a beta of 1.29. The business has a 50-day moving average of $2.03 and a two-hundred day moving average of $2.18. CEL-SCI has a 12 month low of $1.04 and a 12 month high of $3.23.

CEL-SCI (NYSE:CVM) last posted its quarterly earnings results on Wednesday, February 14th. The company reported ($0.14) EPS for the quarter.

Hedge Funds Weigh In On CEL-SCI

Several hedge funds and other institutional investors have recently modified their holdings of the company. Vanguard Group Inc. lifted its stake in shares of CEL-SCI by 9.4% in the 4th quarter. Vanguard Group Inc. now owns 2,079,624 shares of the company’s stock valued at $5,657,000 after purchasing an additional 178,478 shares in the last quarter. Forthright Family Wealth Advisory LLC acquired a new position in CEL-SCI during the 4th quarter worth approximately $45,000. Virtu Financial LLC acquired a new position in CEL-SCI during the 4th quarter worth approximately $163,000. Cantor Fitzgerald L. P. acquired a new position in CEL-SCI during the 4th quarter worth approximately $329,000. Finally, Northern Trust Corp lifted its position in CEL-SCI by 7.2% during the 4th quarter. Northern Trust Corp now owns 83,864 shares of the company’s stock worth $228,000 after acquiring an additional 5,629 shares in the last quarter. 12.08% of the stock is owned by institutional investors and hedge funds.

About CEL-SCI

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers.